Evaluating SGLT2 Inhibitors Empagliflozin and Dapagliflozin for Patients with Acute Decompensated Heart Failure During Ventilator Weaning

What this Trial Is About

Researchers are investigating the possible benefits of sodium-glucose cotransporter 2 SGLT2 inhibitors in patients with acute decompensated heart failure HF who are being weaned off ventilators. The study aims to evaluate if these drugs can help prevent heart-related blood flow problems and lung fluid buildup during the ventilator weaning process. This is a phase 3, open-label, randomized trial sponsored by National Taiwan University Hospital. Patients hospitalized for acute HF will be randomly assigned in a 21 ratio to receive either SGLT2 inhibitors or no SGLT2 treatment. Those in the treatment group will be further randomly assigned to take either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily, starting three days before ventilator weaning. Several tests, including electrocardiograms, chest X-rays, echocardiograms, and blood biomarker measurements, will be performed to monitor heart and lung status at multiple time points before, during, and after the weaning process. Participants will undergo transthoracic echocardiography and blood tests for markers like NT-proBNP and cardiac troponin T at scheduled intervals before starting treatment, during the spontaneous breathing trial, and up to about 90 days after extubation. The study will measure outcomes such as weaning failure, pulmonary edema recurrence, and mortality over 90 days. Safety and treatment effects will be closely followed throughout the study period, which runs up to approximately three months post-extubation.

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning